GSK Will Re-Do Phase II Wellbutrin Metabolite Studies At Higher Dose
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline will need to re-do its Phase II depression program for its metabolite of Wellbutrin (bupropion) after the 60 mg dose failed to meet the primary endpoint
You may also be interested in...
Phase II agent has a safety profile similar to that of Celebrex but offers an “incremental” efficacy benefit over Pfizer’s drug, GSK says. NDA filing is tentatively scheduled for late 2006, but timing may depend on outcome of the Feb. 16-17 FDA advisory committee meeting on COX-2 safety issues.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.